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We develop statistically based methods to detect single nucleotide
DNA mutations in next generation sequencing data. Sequencing gen-
erates counts of the number of times each base was observed at hun-
dreds of thousands to billions of genome positions in each sample.
Using these counts to detect mutations is challenging because muta-
tions may have very low prevalence and sequencing error rates vary
dramatically by genome position. The discreteness of sequencing data
also creates a difficult multiple testing problem: current false discov-
ery rate methods are designed for continuous data, and work poorly,
if at all, on discrete data.
We show that a simple randomization technique lets us use con-
tinuous false discovery rate methods on discrete data. Our approach
is a useful way to estimate false discovery rates for any collection of
discrete test statistics, and is hence not limited to sequencing data.
We then use an empirical Bayes model to capture different sources
of variation in sequencing error rates. The resulting method outper-
forms existing detection approaches on example data sets.
1. Introduction. Highly-multiplex sequencing technologies have made
DNA sequencing orders of magnitude faster and cheaper [Shendure and Ji
(2008)]. One promising application of next generation sequencing technolo-
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gies is detecting changes in the DNA of genetically mixed samples. Examples
of this detection problem include searching for somatic mutations in tumor
tissue contaminated by normal stroma, finding single nucleotide variants by
pooled sequencing of multiple samples, and detecting low-prevalence muta-
tions in evolving virus populations. Our goal is to find genome positions at
which a fraction of the cells or viruses in the sample have mutated. The
studies we consider are exploratory in nature, so any mutations we detect
will be tested further using more laborious methods.
Shendure and Ji (2008) describe the typical sequencing experiment. DNA
from the sample is extracted and fragmented. The fragments are used to
form a DNA library, possibly after amplification and size selection. The ends
of the fragments in the DNA library are sequenced to obtain fixed-length
DNA segments called reads. Aligning the reads to a reference genome yields
counts of the number of times each base (A,C,G,T ) is observed at each
reference position. If every cell or virus in the sample has the same base as
the reference genome at a given position, any observed base different from
the reference base must be due to error. Such errors can be caused by errors
in sequencing or alignment.
We define the observed error rate as the proportion of bases observed at
a given position that are not equal to the reference base. For example, if
the reference base at a position were A and we observed 8 A’s and 2 C’s
at the position, the observed error rate would be 20%. Mutations appear in
sequencing data as unusually high observed error rates. For example, suppose
we know that the true error rate at a given genome position is exactly 1%. If
we observe an error rate of 2% at that position, and if the total count of all
bases observed for that position is sufficiently high to dismiss sampling noise,
then we can infer that roughly 1% of the cells in the sample carry a mutation.
In practice, we do not know the true error rate, which varies widely across
positions and is affected by many steps in the sequencing experiment. Also,
in most sequencing experiments, a large proportion of the positions have few
counts, making it important to account for sampling noise. Distinguishing
true mutations from uninteresting randomness requires statistical modeling
and analysis.
The discrete nature of sequencing data makes the mixed sample detection
problem particularly challenging. It is difficult to detect small, continuous
changes using discrete data. In addition, sequencing depth—the total num-
ber of {A,C,T,G} counts—varies dramatically across positions. For exam-
ple, in targeted resequencing, the sequencing depth can vary over two to
three orders of magnitude [Natsoulis et al. (2011), Porreca et al. (2007)].
Any method must work for both low and high depth positions, which rules
out convenient large-sample approximations.
The discreteness of sequencing data also makes it difficult to tackle multi-
ple testing issues. False discovery rate (fdr ) methods are a standard approach
to controlling type I error in exploratory studies; these methods can be inter-
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preted as empirical Bayes versions of Bayesian hypothesis tests [Benjamini
and Hochberg (1995), Efron et al. (2001), Efron (2004)]. Current fdr meth-
ods, however, are designed for continuous data, and work poorly on discrete
data.
In this paper, we develop an empirical Bayes approach to detect muta-
tions in mixed samples. First, in Section 2, we show continuous fdr methods
can be applied to discrete data. Our basic idea is to replace traditional dis-
crete p-values with randomized p-values that behave continuously, and then
use continuous fdr methods. It is easy to show that the resulting method
preserves the empirical Bayes interpretation of false discovery rates. Our
approach is a useful way to estimate false discovery rates for any collection
of discrete test statistics, and is not limited to sequencing data.
Next, in Section 3, we present an empirical Bayes model for sequencing
error rates. Mutations appear in the data as unusually high error rates, so
to detect mutations accurately, we need to estimate the position-wise error
distribution under the null hypothesis of no mutation. We use a hierarchical
model to separate the variation in observed error rates into sampling vari-
ation due to finite depth, variation in error rate at a fixed position across
samples, and variation in error rate across positions. This model shares infor-
mation across samples and across genome positions to estimate the sequenc-
ing error rate at each position. We use the position- and sample-specific null
distributions from this model to screen for mutations.
Finally, in Section 4, we apply our methods to two very different muta-
tion detection problems. The first problem is motivated by the detection of
emerging mutations in virus samples. We use a synthetic data set created by
Flaherty et al. (2012), where the truth is known, to evaluate the accuracy of
our method and to make comparisons. The second problem is the analysis of
sequencing data from tumor samples with matched normal samples. We use
this larger and more complex data set to illustrate the general applicability
of our methods.
2. Multiple testing tools for discrete data. In this section, we show how
continuous false discovery methods can be applied on discrete data. We begin
by briefly reviewing the basic steps in a standard empirical fdr analysis as
described by Efron (2004), and showing that none of the steps can be directly
applied to discrete data. We then use a randomization technique to translate
each step to the discrete setting.
2.1. A continuous false discovery rate analysis. Consider the following
multiple testing problem. We observe continuous valued data xi, i= 1, . . . , P ,
and, based on a model for the null hypothesis, we have a null distribution Fi
for each xi. We think that most xi are null, and we want to find the few that
are not. For example, our nulls could be normal, Fi =N (0, σ
2
i ), and we could
be searching for unusually large xis. Typically, we use the null distributions
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to form a p-value for each case:
pi = Fi(zi).
The pi’s all have the same distribution under the null, since if xi ∼ Fi,
pi ∼Unif(0,1).
An fdr analysis as outlined by Efron (2004) proceeds in three major steps.
First, we check the validity of our null distributions. If our nulls are correct,
and most xi are null, then most xi ∼ Fi. This means that if our nulls are
correct, most pi ∼Unif(0,1). We can thus use the distribution of the pi to
check if our nulls are correct. If they are, the p-value histogram should be
uniform through most of the unit interval, possibly with some extra mass
near 0 and 1 from truly nonnull xis. If the p-value histogram has this form,
our nulls are at least correct on average [Gneiting, Balabdaoui and Raftery
(2007) make this precise].
Often, however, the p-value histogram reveals that our null distributions
are wrong. If this happens, our next step is to correct our null distributions.
One way to do this is to estimate the null using the data [Efron (2004)].
When our null distributions are wrong, Efron suggests modeling the null
p-values as still having a common distribution, but fitting that distribution
using the data instead of assuming it is Unif(0,1). Since most of our hy-
potheses presumably are null, we can estimate such an “empirical null” by
fitting the distribution of the center of the data. We then use that fitted null
distribution to make better p-values. If H : [0,1] 7→ [0,1] is the cdf of the fit-
ted null p-value distribution, this correction changes our null distributions Fi
to H ◦ Fi and our p-values pi to H(pi).
Finally, once our nulls have been corrected, we can proceed to the final
step of estimating the local false discovery rate
fdr (xi) = P (Hi0|xi),
where Hi0 is the event that the ith null hypothesis is true. Using Bayes’ rule,
and the one-to-one relationship between xi and the transformed p-values,
we can express the false discovery rate as
fdr(xi) =
P (Hi0)fnull(pi)
f(pi)
,(2.1)
where fnull(pi) and f(pi) are the null and marginal distributions of the p-
values. Note that we can reasonably model the p-values as having the same
marginal distribution because they all have the same distribution under the
null.
We estimate the false discovery rate by estimating each of the three quan-
tities on the right side of (2.1). Because we think that most hypotheses are
null, we can simply bound P (Hi0) by 1, and since we have corrected our null
distributions, we know that fnull is the uniform density. Last, we can esti-
mate the marginal distribution f using the observed p-values. Substituting
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Fig. 1. p-values pi = Fi(xi), where xi ∼ Fi =Poisson(10).
these quantities into (2.1) yields an estimated fdr , which we can use to find
nonnull hypotheses based on the magnitudes of the xi’s.
2.2. Discrete data problems. The three core steps in our continuous false
discovery rate analysis are checking the null distributions, possibly estimat-
ing an empirical null, and estimating fdr ’s. Each step relies on the assump-
tion that if we knew the correct null distributions of our test statistics, the
null p-values would be uniform. This assumption fails for discrete data: even
when all of our null distributions are correct, the p-values corresponding to
the truly null hypotheses will still not be uniform, and, in general, will have
different distributions.
For example, suppose we observe data xi, i= 1, . . . , P , and we think that
each xi has the same null distribution Fi = Poisson(10). We can form p-
values pi = Fi(xi) as before. Figure 1 shows that even though our null dis-
tributions are correct, the p-values are far from Unif(0,1). Furthermore, if
the null distributions Fi are Poisson(µi) with µi varying across i, then it is
not hard to see that the pi will have different null distributions. Checking
the uniformity of the p-values does not tell us if our null distribution is cor-
rect or wrong, and it is not clear how to transform the pi to be uniform.
Because the p-values are not uniform under the correct null, we cannot use
the uniformity of the p-values to check our nulls. And since each p-value can
have a different null distribution even when our model is correct, it makes
little sense to model the p-values as having the same null or marginal dis-
tributions. This means that we cannot use existing methods for estimating
empirical nulls and computing fdr ’s on discrete data.
2.3. Randomized p-values. One way to fix this problem is to randomize
the p-values to make them continuous. Randomized p-values are familiar
from classical hypothesis testing [Lehmann and Romano (2005)], and have
long been used in the forecasting literature to assess predictive distribu-
tions for discrete data [Brockwell (2007), Czado, Gneiting and Held (2009),
Kulinskaya and Lewin (2009)] recently used randomized p-values to con-
struct versions of the Bonferroni and Benjamini–Hochberg multiple testing
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procedures for discrete data. Their approach, however, has drawbacks that
make it unsuitable for our purposes. It offers no way to check the nulls, to fit
an empirical null, or to use existing continuous fdr methods. More seriously,
it produces a “probability of rejection” for each case, not a false discovery
rate, and is too computationally expensive to apply to even moderately large
data sets.
We propose using existing continuous false discovery rate methods on
randomized p-values. Let
ri = F
−
i (xi) +Ui(F (xi)−F
−
i (xi))
(2.2)
= PFi(X <xi) +UiPFi(X = xi),
where F−i = P (Xi < xi) denotes the left-limit function of the cdf Fi, Ui
are i.i.d. Unif(0,1) independent of all the xi, and PFi denotes probability
under X ∼ Fi. In other words, we use ri ∼ Unif(F
−
i (xi), Fi(xi)) instead of
pi = Fi(xi).
The key property of ri is that if our null distribution Fi is correct, then
ri ∼Unif(0,1) under the null. This modification (of pi to ri) allows us to ap-
ply continuous fdr methods to the ri. Theorem 2.1 makes this property more
precise: The closer ri is to uniform, the closer our true null distribution is to
the assumed null Fi, and vice versa. The theorem (proved in the Appendix)
also holds for the nonrandom discrete p-value functions proposed by Czado,
Gneiting and Held (2009), which can be used instead of our randomized
p-values in everything that follows.
Theorem 2.1. Let x be a discrete random variable, F be our predicted
distribution for x, and G be the true distribution of x. Let r = F−(x) +
U(F (x)−F−(x)) be our constructed randomized p-value, with density h(r),
cdf H(r), and let hunif(t) = 1, Hunif(t) = t be the uniform density and cdf.
Then
DKL(Hunif‖H) =DKL(G‖F ),
DKL(H‖Hunif) =DKL(F‖G),
sup
r∈[0,1]
|H(r)−Hunif(r)|= sup
x
|F (x)−G(x)|,
where for two distribution functions P and Q, DKL(P‖Q) =
∫
log(dP
dQ
)dP is
the Kullback–Liebler divergence. In particular, r ∼ Unif(0,1) if and only if
F =G.
Theorem 2.1 says that if our null distribution Fi is correct, then ri is
uniform under the null. Moreover, if our null distribution is close to the true
null in the Kullback–Liebler or Kolmogorov distance, then r is close to uni-
form in the same sense under the null. Consider our previous example, where
xi ∼ Poisson(10). Figure 2 shows that ri are uniform if we use the correct
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Fig. 2. Histograms of randomized p-values ri under the correct Poisson(10) null (left)
and the incorrect Poisson(5) null (right). The Kolmogorov distance between the distri-
bution of ri under the incorrect null and the uniform distribution is 0.6464, exactly the
Kolmogorov distance between Poisson(5) and Poisson(10). The distance from the empiri-
cal cdf of the realized ri in the histogram to the uniform distribution is 0.6465, which is
different only because of the randomness in x and r.
Poisson(10) null. If we use the wrong null, Poisson(5), then ri are clearly
not uniform. The distance between the distribution of ri and the uniform
distribution is exactly the distance between the assumed null Poisson(5) and
the correct null Poisson(10).
Theorem 2.1 lets us check our null distributions, fit empirical null distribu-
tions, and estimate false discovery rates using tools developed for continuous
data. Consider the first problem, checking the null distributions. We know
that most xi each come from their null distribution, and that if we have
assumed the correct null distributions, ri ∼ Unif(0,1) under the null. We
can check for systematic departures from the assumed null distributions by
assessing the ri histogram just as we checked our nulls using the p-value
histogram for continuous data, using any model assessment tool from the
continuous fdr literature.
Next, consider estimating an empirical null distribution. We can use con-
tinuous empirical null methods to fit a null distribution H to ri. Just as in
the continuous case, we can then use H to fix our null distributions, chang-
ing Fi to F˜i = H ◦ Fi, and substituting F˜ in place of F in (2.3) to make
new randomized p-values r˜i. Theorem 2.1 says that if r˜i is approximately
uniform, F˜i is close to the true null distribution.
Finally, consider estimating fdr . Using Bayes’ rule, we can write
fdr (xi) =
P (Hi0)Pnull(xi)
Pmarg(xi)
,
where Pnull and Pmarg are the null and marginal distributions of xi. Rewriting
in terms of r˜i, this is,
fdr (xi) =
P (Hi0)Pnull(r˜i ∈ [F˜
−
i (xi), F˜i(xi)])
Pmarg(r˜i ∈ [F˜
−
i (xi), F˜i(xi)])
.(2.3)
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As before, we bound P (Hi0) by 1, and since r˜i are uniform under the null,
Pnull(r˜i ∈ [F˜
−
i (xi), F˜i(xi)]) = F˜i(xi)− F˜
−
i (xi).
We can model the r˜i as having approximately the same marginal distribution
since they are all Unif(0,1) under the assumed null distribution. This lets
us use the distribution of r˜i to estimate the marginal probability in the
denominator of (2.3). Substituting these three values into (2.3) gives us an
estimated false discovery rate. Randomization thus lets us translate the three
key steps in a continuous fdr analysis to the discrete setting.
It is important to note that although we use randomized p-values, the
variability in the randomization does not significantly affect our final fdr es-
timates. Given F˜ , the false discovery rate in (2.3) is a deterministic function
of the data x, so the randomization step affects our fdr estimate only through
the estimated empirical null F˜ and the marginal distribution of r˜i. These
quantities depend on the empirical distribution of all or most of the r˜i’s, and
do not depend strongly on any individual r˜i. For large P , the empirical dis-
tribution of r˜i will be close to its true distribution, which is a deterministic
function of the xi’s. Thus, for large P , the variability in the randomization
will have little effect on our fdr estimates. For small P , if the extra variability
from randomization is a concern, we can substitute the nonrandom p-value
functions proposed by Czado, Gneiting and Held (2009) with essentially no
change to our analysis.
3. Modeling sequencing error rates. In this section, we turn to the ap-
plication of detecting DNA mutations and present an empirical Bayes model
for sequencing error rates. Mutations appear in the data as unusually high
observed error rates, so detecting mutations accurately requires understand-
ing the normal variation in error rates. We begin by describing two example
data sets and summarizing the existing approaches. Then, we describe a hi-
erarchical model for observed error rates that accounts for sample effects,
genome position, and finite depth. Our model shares information across po-
sitions and samples to estimate error rates and quantify their variability.
3.1. Example data sets: Virus and tumor. Our first example is moti-
vated by the problem of detecting rare mutations in virus and microbial
samples. Deep, targeted sequencing has been used to identify mutations
that are carried by a very small proportion of individuals in the sample.
Detecting these rare mutations is important, because they represent quasis-
pecies that may expand after vaccine treatment. We use the synthetic DNA
admixture data from Flaherty et al. (2012), in which a reference and a mu-
tant version of a synthetic 281 base sequence are mixed at varying ratios.
The mutant differs from the reference at 14 known positions. This data set
contains six samples, 3 of which are 100% reference, the other 3 contain
a 0.1% mixture of the mutant sequence. These samples were sequenced on
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an Illumina GAIIx platform. The reads were then aligned to the reference
sequence, yielding nonreference counts (“errors”) xij and depth Nij for each
position (i= 1, . . . , P = 281, j = 1, . . . , S = 6) [see Flaherty et al. (2012) for
more details]. Our goal is to find the mutations, which appear in the data
as unusually large error rates xij/Nij .
Our second example is a comparison of normal and tumor tissue in S = 28
lymphoma patients, plus tissue from one healthy individual sequenced twice
as a control. A set of regions containing a total of P = 309,474 genome
positions was extracted from each sample and sequenced on the Illumina
GAIIx platform, yielding nonreference counts xij , yij and depths Nij,Mij
for the normal and tumor tissues. Our goal is to find positions that show
biologically interesting differences between the normal and tumor samples,
such as positions that are mutated in the tumor or variant positions in the
normal that have seen a loss of heterozygosity. These appear in the data as
significant differences between the error rates xij/Nij and yij/Mij .
The two detection problems pose different challenges. Since virus genomes
are short, they can be sequenced to uniformly high depth. For example, the
synthetic virus data from Flaherty et al. (2012) has depth in the hundreds
of thousands. Human tissue, however, is usually sequenced to a lower, more
variable depth. The tumor data has a median depth of 171, but the depth
varies over five orders of magnitude, from 0 to over 100,000. Discreteness
is thus a more serious problem for the tumor application than it is for the
virus application. The tumor data also exhibits much more variation in error
rates, from less than 0.1% to over 20%, because the human genome is harder
to target and map.
Analyzing the virus data is difficult primarily because we are interested
in very rare mutations. A mutation carried by 0.1% of the viruses may be
biologically interesting, but one carried by 0.1% of the tumor cells is typically
less interesting, since biologists usually are interested in mutations present in
a substantial fraction of the tumor cells. Despite the high sequencing depth,
it is difficult to detect such a small change in base proportions using discrete
counts.
3.2. Existing approaches. Most current methods for variant detection in
sequencing data are designed to analyze samples of DNA from pure, possibly
diploid, cells. In pure diploid samples, variants are present at levels of either
50% or 100% of the sample, and are thus much easier to detect than variants
in mixed samples, where they may be present at continuous fractions. Nearly
all existing methods, including the widely used methods of Li, Ruan and
Durbin (2008) and McKenna et al. (2010), rely on sequencing quality scores
from the Illumina platform and mapping quality metrics to identify and
filter out high-error positions. Storing and processing these quality metrics
is computationally intensive, and methods utilizing these metrics are not
portable across experimental platforms.
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Muralidharan et al. (2012) proposed a method to detect single nucleotide
variants in normal diploid DNA. Their method uses a mixture model with
mixture components corresponding to different possible genotypes, and pools
data across samples to estimate the null distribution of sequencing errors at
each position. They showed that this approach, which avoids using quality
metrics, outperforms existing quality metric based approaches.
A different approach to variant detection was proposed by Natsoulis et al.
(2011), who use techniques based on domain knowledge, such as repeat
masking (see Section 4.2) and double-strand confirmation (evidence for the
variant must be present in both the forward and reverse reads covering
the position) to identify high-error positions and eliminate false calls. This
method can also be used to call mutations in tumors using matched normal
samples.
Although most current methods for variant detection are designed for pure
diploid samples, a few methods for detecting rare variants in virus data have
recently been proposed. Hedskog et al. (2010) find simple upper confidence
limits for the error rate and use them to test for variants. Flaherty et al.
(2012) use a Beta-Binomial model, that is, less conservative but much more
powerful. Their model for sequencing error rates is similar in form to ours,
but uses a Beta distribution for error rates that we find does not fit the data.
Hedskog et al. (2010) and Flaherty et al. (2012) also do not account for the
effects of sample preparation on the error rates. Finally, both papers simply
use a Bonferroni bound to avoid multiple testing concerns. This is reasonable
since the data they analyze have only a few hundred positions, but it makes
their methods inapplicable to large genomic regions where multiple testing
is a more serious problem.
3.3. Sequencing error rate variation. Sequencing error rates show three
types of variation. The first type of error rate variation comes from finite
depth. Consider a nonmutated position, where all nonreference counts are
truly errors. Given the depth and an error rate, we can model the nonrefer-
ence counts as binomial,
x∼ Binomial(N,p).(3.1)
Because N is finite, the observed error rate x/N will vary around the true
error rate p. This type of variation is easily handled by the binomial model.
The second type of variation is positional: as shown by Muralidharan
et al. (2012) and Flaherty et al. (2012), different positions in the genome
have different error rates. This means that each position has its own error
rate p in our binomial model (3.1). Suppose we have extremely large depth,
so that the binomial variation in the observed error rate x/N is negligible.
A large observed error rate at a given position is still not enough to report
a mutation, because that position may simply be noisy. We can account for
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Fig. 3. Observed error rates logit(x/N) for two reference samples in the virus data. The
solid green line is the x= y diagonal. The error rates for the second sample are slightly
but significantly biased upward. The dashed blue line shows the diagonal shifted to account
for this bias.
the positional variation in error rates by aggregating data across samples to
estimate the baseline sequencing error p at each position.
The last type of variation is variation across samples. Small differences in
sample preparation and sequencing, such as the sample’s lane assignment on
the Illumina chip, can create differences in the sequencing error rate at each
position, even when the sample contains no mutations. For example, suppose
that we have extremely large depth, that we have estimated the positional
error rate p perfectly, and that we observe an error rate x/N , that is, higher
than p. We still cannot conclude that the position is mutated, because the
difference between x/N and p may be due to sample preparation. We can
account for cross-sample variation by aggregating data across positions to
estimate sample effects.
Figure 3 illustrates these three sources of variation. It plots, on the logit
scale, observed error rates x/N for two reference samples from the synthetic
data of Flaherty et al. (2012). Each point in the plot represents a position.
There are no mutant positions, so all points represent null observed error
rates. The figure shows that error rates in the two samples are highly cor-
related and depend strongly on genome position. The binomial variation
due to finite depth causes some of the spread around the diagonal. Sample
variation also causes spread around the diagonal, as well as a systematic
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Fig. 4. Differences between observed error rate x/N and positional error rate µ for
the three reference samples, on the logit scale. The mean error rate µ was estimated by
averaging logit(x/N) for each position over the reference samples.
bias-error rates for the second sample are slightly but significantly higher
than error rates in the first. These two samples were actually sequenced in
the same lane; we observed stronger sample effects when comparing data
from different lanes. We also saw similar behavior on the tumor data.
3.4. Modeling the variation. Figure 3 also suggests a model for sequenc-
ing error rates—when plotted on the logit scale, the error rates are dispersed
evenly around a shifted diagonal. Figure 4 shows that the dispersion in error
rates is roughly normal. Accordingly, we can model the logit sequencing er-
ror rate in each sample as a sum of a positional error rate, sample bias, and
normally distributed sample noise. Given the error rate, we observe binomial
counts. This model makes sense biologically: sample preparation for these
two data sets includes PCR amplification, an exponential process, so it is
plausible that differences in sample preparation produce additive effects on
the logit scale.
This formulation yields the following hierarchical model for the unmatched
mutation detection problem such as in the virus application:
logit pij ∼N (logitµi+ δj , σ
2
j ),
(3.2)
xij |pij ∼ Binomial(Nij , pij),
where µi is the positional error rate, δj is a sample-specific error rate bias
(constant across positions), and σj measures the sample specific noise in
error rates. Fitting µ, δ, and σ provides information on the positional error
rates, sample biases, and cross-sample variability in our data.
This model allows us to test whether an observed error rate is unusual
enough to be a mutation. For example, consider applying the model to the
virus data. Once we fit the parameters, as described in Section 3.4.1, the
model gives a null distribution for the observed error rate at each position.
We can then compare the observed error rates for each position in a clinical
sample to its null distribution and use the false discovery rate methods from
Section 2 to find mutated positions.
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Next, consider tumor data with matched normals. We model the normal
tissue error rates as in (3.2), and introduce extra parameters to account for
additional error rate variation between normal and tumor tissue from the
same patient:
logit pij ∼N (logitµi + δj , σ
2
j ),
logit qij|pij ∼N (logit pij + ηj , τ
2
j ),
xij|pij , qij ∼ Binomial(Nij , pij),
yij|pij , qij ∼ Binomial(Nij , qij),
where pij , qij are the normal and tumor error rates, respectively; δj , ηj are
sample effects, σj is the noise variance for the normal tissue, and τj is the
noise variance for the difference between tumor and normal tissue. After
fitting the parameters as described in Section 3.4.1, we use this model to find
the conditional null distribution for the tumor error rates, given the observed
normal error rates. That is, we use the model to find null distributions for
yij
Mij
∣∣∣∣ xijNij ,
and then use the false discovery rate approach in Section 2 to find mutated
positions.
The logit-normal model naturally handles the discreteness and wide range
of depths in our data. It separates the observed error rate variation into
depth, positional variation, and sample effects, and combines the different
sources of variation to give the appropriate null distribution in each case.
3.4.1. Fitting. The best way to fit our model will depend on the data
set, so we will discuss the fitting in only general terms.
Estimating µ, δ, and η is usually straightforward. For example, in the virus
data set, we use the median of the observed error rates for each position over
all of the reference samples to estimate µ, then estimate δ using all of the
positions in each sample,
δˆj =median
(
logit
xij
Nij
− logit µˆi
)
.
Similar ideas can also be applied to estimate these parameters for the tumor
data.
Estimating the sample error rate variances σ and τ can be more difficult.
The simplest and fastest approach is to use the method of moments as
an approximate version of maximum likelihood. This works well if depths
are large, as in the virus data. If depths are small, as in the tumor data,
the method of moments works badly and it is better to use the maximum
likelihood.
14 O. MURALIDHARAN ET AL.
The tumor data also has extra sources of variability, which we discuss
briefly to illustrate how our method can be adapted to the specific char-
acteristics of a data set. Because of genetic variation between people, not
all normal samples have the same base at each position. For example, at
single nucleotide polymorphic positions (SNPs), heterozygous samples have
an observed “error rate” close to 0.5 against the reference genome, while
homozygous samples have an observed error rate close to 0. We account for
SNP positions by using a simple mixture model to genotype the samples and
estimating µi separately for each genotype. We also increase σ
2
j for positions
with multiple genotypes to account for the extra uncertainty due to possibly
incorrect genotyping.
Another source of extra variability comes from the technology used to gen-
erate our data set: The 309,474 genome positions are regions of the genome
that have been targeted by primers and amplified. We observe empirically
that regions treated with some primers have more variable error rates across
samples. These regions can be identified using extra data generated by the
sequencer. We account for this extra variability by fitting different error
variances σj and τj for each genomic region, and using a high quantile of
the region-wise variabilities as our σj .
The logit-normal prior for p makes it difficult to calculate the marginal
distributions of counts, find predictive distributions, and fit σ, τ by maxi-
mum likelihood. We approximate the logit-normal distribution with a Beta
distribution. If
p∼ Beta
(
1
σ2(1− µ)
,
1
σ2µ
)
,
then it is easy to show using Stirling’s formula that logit p has approximate
mean logitµ, variance σ2, skewness
σ(µ3 − (1− µ)3),
and excess kurtosis
2σ2(µ4 + (1− µ)4).
If σ is small and µ is close to 0 or 1, as they are in our data, then logit p is
approximately N (logitµ,σ2). This Beta approximation makes it much easier
to calculate marginal and posterior distributions.
4. Results.
4.1. Virus data. We first tested our method by applying it to the virus
data, described in Section 3.1. In this synthetic data, we know the locations
of the 14 variant positions, and we know that the mutant base is present in
0.1% of the viruses in each case. We did not use any information about the
mutations’ location or prevalence when fitting our model. Thus, we can use
this data to evaluate our method’s power and specificity.
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Fig. 5. Histogram of p-values for the virus data, reference samples (top plot) and clinical
samples (bottom plot).
Our model fits the data reasonably well. Figure 5 shows the p-values his-
tograms for the reference and clinical samples; randomization is unnecessary
since the depth is so high (the median depth is 775,681, and 95% of positions
have depth between 271,192 and 1,689,977). The p-values are fairly uniform
for the reference samples, and also uniform in the clinical samples except
for a spike near 0 that indicates that some positions are truly nonnull. Since
our null distributions fit the data accurately enough, we did not need to
estimate an empirical null. We used the log-spline fdr estimation method
proposed by Efron (2004) to estimate the false discovery rate ˆfdr ij for each
position in each sample. Finally, we declared any position with ˆfdr less than
a given threshold to be a mutation.
Table 1 compares our results to the method of Flaherty et al. (2012). Our
method produces fewer false discoveries while maintaining excellent power.
Table 1
Detection results on clinical samples of the synthetic virus data
Our method, Our method,
ˆfdr ≤ 0.1 ˆfdr ≤ 0.01 Flaherty et al.
True positives (of 42) 42 39 42
False positives 1 0 10
Power 100% 93% 100%
False positive rate 2.32% 0% 19.23%
16 O. MURALIDHARAN ET AL.
If we use an ˆfdr threshold of 10%, our method detects all 42 mutations (14 in
each clinical sample) and makes 1 false discovery, for a false positive rate of
2.3%. A more stringent fdr threshold of 1% eliminates all false discoveries,
at the cost of missing 3 mutations. Our method’s high power and low false
discovery rate is especially notable given that the mutation is only present
at 0.1% within the sample.
4.2. Tumor data. Next, we applied our method to the tumor data, also
described in Section 3.1. Our model fits the data relatively well, but not as
accurately as it fits the virus data. We can assess the model by examining
the last sample pair, which actually consists of a healthy person’s normal
tissue that was sequenced twice as though it were normal and tumor tissue.
Figure 6 shows the histogram of randomized and unrandomized p-values
for the last sample pair. The randomized p-values rij are uniform through
most of the unit interval, indicating that most of our fitted null distributions
are close to the true null distributions. In contrast, the unrandomized p-value
histogram tells us next to nothing about our null distributions.
Our null distributions do not give a perfect fit: the rij appear to be en-
riched near 0 and 1, so if we thought the null were uniform, our false dis-
covery rates would be misleadingly small near 0 and 1. Empirical nulls are
not very helpful here, because they are fit to the center of the distribution
rather than the tails. Inspecting the sample reveals that the null distribution
is enriched near 0 and 1 because the error rates p and q are more variable
very close to 0 and 1 than our normal model predicts. We will discuss this
issue a bit more later.
Fig. 6. Randomized rij (top plot) and unrandomized pij (bottom plot) values for the last
normal tumor pair (actually the same normal tissue sequenced twice).
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Fig. 7. Randomized p-values ri for the seventh normal tumor pair. This sample had the
least uniform ri.
Although our null distributions are mostly correct for the last sample,
they are not as good on some other samples. Figure 7 shows the random-
ized p-value histogram for the seventh sample pair, which shows the most
deviation from uniformity. The underdispersion in Figure 7 means that our
null distributions are systematically too wide on that sample.
We fit empirical nulls to correct our null distributions. Figure 8 shows
a normal quantile–quantile plot of randomized p-values for sample 7, trans-
formed to the normal scale by zij = Φ
−1(rij). The QQ plot is straight
through the bulk of the data, indicating that our null can be corrected
by centering and scaling on the normal scale. Our corrected null will still be
too light-tailed in the far tails, but, as for the last sample, these points cor-
respond to very small changes in error rate very close to 0 and 1, which we
will discuss later. Accordingly, we used the median and a robust estimator
of scale [Sn, described by Rousseeuw and Croux (1993)] on zij to estimate
a location and scale for our empirical null in each sample. Figure 9 shows
that this yielded much more uniform randomized p-values.
Fig. 8. Normal QQ plot of zij =Φ
−1(rij) for sample 7.
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Fig. 9. Empirical null randomized p-values r˜i for the seventh normal tumor pair. The
empirical null yields much more uniform p-values (compare to Figure 7).
Finally, we estimated the density of the empirical null adjusted random-
ized p-values using a log-spline. We then estimated the fdr . To ease com-
putation, we approximated the fdr expression in equation (2.3). Instead of
estimating
Pmarg(r˜i ∈ [F˜
−
i (xi), F˜i(xi)]),
we fit fmarg and used the approximation
Pmarg(r˜i ∈ [F˜
−
i (xi), F˜i(xi)])(4.1)
≈ fˆmarg(
1
2(F˜
−
i (xi) + F˜i(xi)))(F˜i(xi)− F˜
−
i (xi)).(4.2)
Substituting (4.2) into (2.3) yields an estimate of the false discovery rate ˆfdr ij
for each position in each sample.
As mentioned, many positions had a low ˆfdr while being biologically un-
interesting due to the heavier tail of the null p-value distribution around 0
and 1. Our model looks at differences between normal and tumor error rates
on the logit scale, which exaggerates differences near 0 and 1; for example,
on the logit scale, 0.001 and 0.003 are as far from each other as 0.5 and 0.75.
Such small changes near 0 and 1 are also more likely to be false positives,
since null error rates are more variable very near 0 and 1 than our model
predicts. Even if they were real, mutations present at such small fractions
in tumor tissue are too rare to be biologically interesting. For most tumor
analysis scenarios, we want to find mutations that are present in a fairly
large fraction of the cells in the tumor tissue, with the prevalence threshold
determined by the biologist.
To find such mutations, we estimated the change in error rate at each
position for each sample using a very simple “spike and slab” model. We
supposed that either the normal and tumor error rates were the same, or
they were different, in which case we knew nothing about either. Under this
model, the expected error rate difference given the data is
∆ij =E(qij − pij|x, y)
= P (qij 6= pij |x, y)
(
yij
Mij
−
xij
Nij
)
,
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which we can estimate by
∆ˆij = ˆfdr ij
(
yij
Mij
−
xij
Nij
)
.
We required a position to have a large ∆ˆ (|∆ˆ| ≥ 0.25) as well as a low ˆfdr
( ˆfdr ≤ 0.1) to be called a biologically interesting mutation.
Thresholding for both false discovery rate and estimated effect size yielded
427 mutation calls on the clinical samples. Assessing these calls is difficult.
Unlike for the synthetic data, we do not know which positions are truly
mutated or null for the tumor data. Since all putative mutations in the tumor
samples are new changes, and would be unique to each sample, we cannot
assess our mutation calls using databases of known variants. Also, targeted
deep resequencing is currently the best technology for variant detection, so,
short of resequencing the entire genomic region at even higher depth, we
cannot use some other gold-standard experimental method to validate our
calls.
We therefore use a simple domain-knowledge based proxy, enrichment in
repetitive regions, as a crude check that our method gives useful results.
Repetitive regions are segments of DNA that repeat themselves with high
sequence similarity at multiple places in the genome. They confuse the DNA
targeting, extraction, and mapping steps in the experiment, and have been
a major source of false calls for previous variant detection methods. Because
of this, most existing variant detection methods use repeat detection algo-
rithms to find repetitive regions, and then use the output of these algorithms
to refine their calls. The most common approach has been to simply ignore
calls in regions that are designated as repetitive, since otherwise the calls
would be dominated by false calls in these regions.
Masking repetitive regions has some disadvantages. First, different repeat
detection algorithms often disagree, so the choice of repeat detection method
and associated parameters can substantially impact the final list of calls. Sec-
ond, many functional areas of the genome, such as exons, contain repeated
genetic material. For example, roughly 8.5% of our tumor data, which con-
sists almost entirely of exons, lie in repetitive regions (the exact percentage
depends on the repeat detector and parameters used). If we simply ignore
mutation calls in repetitive regions, we may miss important mutations in
functional regions.
Our approach does not rely on any information about whether a position
lies in a repetitive region. The high error rates in repetitive regions are re-
producible across samples, and thus by modeling the error rate as a function
of genome position, we can account for the higher error rates in repetitive
regions without using any explicit information about repetitiveness.
Of the 427 mutations found in the tumor data by our method, 95 (22.1%)
lie in repetitive regions. In comparison, Natsoulis et al. (2011) make 1305
calls before their final repeat masking step, 470 (36%) of which are in repeti-
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tive regions. Although our calls are somewhat enriched in repetitive regions,
they are less enriched than the calls made by Natsoulis et al. (2011) before
repeat masking, despite not using any domain knowledge explicitly. This is
a rough indication that our positional error-rate model is estimating higher
error rates in repetitive regions.
Our method makes more calls than Natsoulis et al. (2011) in low depth
regions. We make a 233 gain of allele calls, 47 (20.1%) of which are in
repetitive regions. Of the 186 calls we make outside of repetitive regions,
103 are among the 165 gain of allele calls made by Natsoulis et al. (2011).
Nearly half of the 83 calls made by our method outside repetitive regions
and not made by Natsoulis et al. (2011) are in low depth regions of the
genome. We would like to think that this indicates our method is able to
achieve higher power in low depth regions by pooling data across samples to
estimate the null distribution of the error rates. We cannot know the truth,
however, without a rigorous validation experiment.
4.3. Summary. In this paper, we have shown that empirical Bayes ideas
can be usefully applied to detect mutations in high throughput sequencing
data from mixed DNA samples. We used a hierarchical model to account
for different sources of variation in sequencing error rates. This model let us
weigh the different sources against one another, and naturally accommodates
the discreteness and depth variation in our data. We also adapted contin-
uous fdr methods to discrete data using a simple randomization scheme.
Combining the new multiple testing methods with the empirical null dis-
tributions for sequencing error rates yielded a powerful, statistically sound
way to detect mutations in mixed samples.
APPENDIX
We prove Theorem 2.1, which justifies the use of randomized p-values.
From the construction of r, we have that
r|x∼Unif(F−(x), F (x)).
Thus, the unconditional density of r is
h(r) =
∑
x
PG(x)
PF (x)
Ir∈[F−(x),F (x)],
where PF and PG denote probability under F and G respectively. This means
that
DKL(Hunif‖hH) =
∫
log
(
h(r)
hunif(r)
)
h(r)dr
=
∑
x
∫ F (x)
F−(x)
PG(x)
PF (x)
log
[
PG(x)
PF (x)
]
dr
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=
∑
x
PG(x) log
PG(x)
PF (x)
=DKL(G‖F ).
The other Kullback–Liebler equality is proved similarly.
For the Kolmogorov distance, note that the cdf of r, H , is piecewise
linear, and the uniform cdf Hunif(r) = r is also linear. This means that
|H −Hunif | reaches its maximum at one of the knots of H , and these are 0,
1, and F (x) for all possible values of x. Since H(0) = Hunif(0) = 0 and
H(1) = Hunif(1) = 1, the maximum has to occur at some F (x). At these
points, though,
H(F (x)) = PG(r≤ F (x))
=
∑
x∗≤x
(F (x∗)− F−(x∗))
PG(x
∗)
PF (x∗)
=G(x)
so
sup
r
|H(r)−Hunif(r)|= sup
x
|H(F (x))− F (x)|
= sup
x
|G(x)−F (x)|.
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